We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-4.72%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$419M
AUM Growth
-$65M
Cap. Flow
-$3.77M
Cap. Flow %
-0.9%
Top 10 Hldgs %
66.43%
Holding
32
New
4
Increased
–
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
CAMP icon
CAMP4 Therapeutics
CAMP
+$24.1M
2
AKRO
Akero Therapeutics
AKRO
+$5M
3
ALEC icon
Alector
ALEC
+$3.75M
4
TARA icon
Protara Therapeutics
TARA
+$2.58M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$12.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$7.52M
3
COGT icon
Cogent Biosciences
COGT
+$6.07M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$5.24M
5
ELVN icon
Enliven Therapeutics
ELVN
+$3.17M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$282M
$76.2M 18.19%
4,408,379
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$4.15B
$36.7M 8.75%
1,629,765
-122,409
-7% -$3.17M
SKYE icon
3
Skye Bioscience
SKYE
$20.5M
$28.1M 6.69%
9,913,168
– –
TECX
4
Tectonic Therapeutic
TECX
$527M
$27.5M 6.57%
596,660
-49,864
-8% -$2.11M
ARTV
5
Artiva Biotherapeutics
ARTV
$523M
$23.7M 5.66%
2,353,304
– –
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.8B
$22.4M 5.35%
1,027,711
-203,908
-17% -$5.24M
BHVN icon
7
Biohaven
BHVN
$2.01B
$17.9M 4.27%
478,972
– –
PHVS icon
8
Pharvaris
PHVS
$2.25B
$15.3M 3.65%
797,600
– –
MLTX icon
9
MoonLake Immunotherapeutics
MLTX
$1.48B
$15.3M 3.65%
282,313
– –
CAMP icon
10
CAMP4 Therapeutics
CAMP
$219M
$15.3M 3.65%
+2,927,915
New +$24.1M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$14.1M 3.37%
736,595
– –
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$13.9M 3.32%
830,945
-454,055
-35% -$7.52M
ERAS icon
13
Erasca
ERAS
$6.19B
$13.6M 3.24%
5,405,404
– –
PRAX icon
14
Praxis Precision Medicines
PRAX
$8.52B
$13.1M 3.12%
170,000
-170,000
-50% -$12.3M
TYRA icon
15
Tyra Biosciences
TYRA
$1.91B
$13.1M 3.12%
939,298
– –
CLDX icon
16
Celldex Therapeutics
CLDX
$2.96B
$12.6M 3%
497,270
– –
EYPT icon
17
EyePoint Inc
EYPT
$1.04B
$7.82M 1.87%
1,050,000
– –
VKTX icon
18
Viking Therapeutics
VKTX
$3.8B
$7.63M 1.82%
189,593
-47,967
-20% -$2.74M
VOR icon
19
Vor Biopharma
VOR
$1.16B
$7.06M 1.69%
318,086
– –
ANAB icon
20
AnaptysBio
ANAB
$1.59B
$4.74M 1.13%
357,733
– –
AKRO
21
DELISTED
Akero Therapeutics
AKRO
$4.59M 1.1%
+165,000
New +$5M
SCPH
22
DELISTED
scPharmaceuticals
SCPH
$4.25M 1.01%
1,200,647
– –
TARA icon
23
Protara Therapeutics
TARA
$223M
$4.22M 1.01%
+800,000
New +$2.58M
GHRS icon
24
GH Research
GHRS
$1.93B
$4.01M 0.96%
572,665
– –
RLYB icon
25
Rallybio
RLYB
$84.6M
$3.49M 0.83%
453,841
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q4 2024 Portfolio in Review

As of Q4 2024, 5AM Venture Management held 32 positions worth $419M, down 13% from $484M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

5AM Venture Management's Q4 2024 filing shows 4 new, 6 reduced and 1 closed positions. Its largest new stake was CAMP4 Therapeutics: 2,927,915 shares worth $15.3M. The largest sale was Praxis Precision Medicines, an estimated $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q4 2024 buy was CAMP4 Therapeutics: 2,927,915 shares worth $15.3M.
  • 5AM Venture Management's biggest Q4 2024 reduction was Praxis Precision Medicines, cutting an estimated $12.3M.
  • 5AM Venture Management fully exited Cogent Biosciences in Q4 2024, selling an estimated $6.07M.
  • 5AM Venture Management's ten largest holdings make up 66% of its $419M portfolio in Q4 2024.
  • 5AM Venture Management opened 4 new positions and closed 1 in Q4 2024.
  • 5AM Venture Management's portfolio value fell 13% quarter-over-quarter to $419M.

Based on 5AM Venture Management's 13F filing for Q4 2024, filed 14 Feb 2025.